RE:RE:RE:New and improvedSorry. Typo. Trial instead of trail
I am one of those who can't believe that MCNA has been put on a shelf with almost no value
attached to it. So much time, efforts, dilution, and shareholder's money have been put into it. At one point ENDO and Ipsen were among those who also saw its tremendous potential. It could have easily been worth over $1 billion if the panel had voted yes and the FDA given their thumbs up. A 18-6 results seems decisive, but really most urologists on the comity were in favor of the approval and i think that most of the "no" votes could have been turned around if the trial design had been somewhat more robust So MCNA is worth nothing? Really? I don't get it. The unmet medical needs are huge, the safety profile is great, and the potential antitumor activity looks quite promising in my opinion. I don't see why a major biotech or pharma wouldn't pay $100M+ for this platform and give it another try.
https://www.onclive.com/web-exclusives/fda-panel-rejects-immunotherapy-mcna-in-bladder-cancer